Gensia, Sankyo deal

The companies will develop drugs to treat non-insulin dependent (Type II) diabetes. GNSA will

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE